Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature
Journal of Infection and Public Health2021Vol. 14(4), pp. 474–477
Citations Over TimeTop 16% of 2021 papers
Fatehi Elzein, Ahmed Ibrahim, Fatimah Alshahrani, Mervat Mahrous, Esam Murshid, Turki Aldhehyan, Ghadah Almutiri, Meshal Altowairqi, Medina Ahmed, Mohammed Alsaeed, Eid Alsufyani, Nouf Alnawshan
Abstract
Covid19 reinfection Recurrent COVID-19 is increasingly reported. However; other etiologies including superadded infection or pulmonary embolism should be ruled out, particularly if recurrence occurs less than 3 weeks.
Related Papers
- → Tocilizumab for treating juvenile idiopathic arthritis(2016)27 cited
- → The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment(2014)1 cited
- → OA31 Real life experience of tocilizumab treatment for giant cell arteritis(2023)1 cited
- → Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2(2020)
- → Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease(2021)